ATE251627T1 - Verfahren und kristallformen von 2- methylthienobenzodiazepinen - Google Patents

Verfahren und kristallformen von 2- methylthienobenzodiazepinen

Info

Publication number
ATE251627T1
ATE251627T1 AT00203573T AT00203573T ATE251627T1 AT E251627 T1 ATE251627 T1 AT E251627T1 AT 00203573 T AT00203573 T AT 00203573T AT 00203573 T AT00203573 T AT 00203573T AT E251627 T1 ATE251627 T1 AT E251627T1
Authority
AT
Austria
Prior art keywords
methylthienobezodiazepines
crystal forms
crystal
forms
Prior art date
Application number
AT00203573T
Other languages
English (en)
Inventor
Charles Arthur Bunnell
Barry Arnold Hendriksen
Samuel Dean Larsen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE251627(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE251627T1 publication Critical patent/ATE251627T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
AT00203573T 1995-03-24 1996-03-22 Verfahren und kristallformen von 2- methylthienobenzodiazepinen ATE251627T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24

Publications (1)

Publication Number Publication Date
ATE251627T1 true ATE251627T1 (de) 2003-10-15

Family

ID=23621056

Family Applications (4)

Application Number Title Priority Date Filing Date
AT96302000T ATE204280T1 (de) 1995-03-24 1996-03-22 Kristallformen eines thieno(2,3-b)(1, 5)benzodiazepinderivates und verfahren zu deren herstellung
AT00203573T ATE251627T1 (de) 1995-03-24 1996-03-22 Verfahren und kristallformen von 2- methylthienobenzodiazepinen
AT0902196A AT406771B (de) 1995-03-24 1996-03-22 Neue kristalline form von 2-methyl-4-(4-methyl- 1-piperazinyl)-1oh-thieno (2,3-b) (1,5)-benzodiazepin, verfahren zu deren herstellung, pharmazeutische mittel und deren verwendung
AT03077455T ATE331719T1 (de) 1995-03-24 1996-03-22 Verwendung von kristallformen von 2- methylthienobenzodiazepinen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT96302000T ATE204280T1 (de) 1995-03-24 1996-03-22 Kristallformen eines thieno(2,3-b)(1, 5)benzodiazepinderivates und verfahren zu deren herstellung

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT0902196A AT406771B (de) 1995-03-24 1996-03-22 Neue kristalline form von 2-methyl-4-(4-methyl- 1-piperazinyl)-1oh-thieno (2,3-b) (1,5)-benzodiazepin, verfahren zu deren herstellung, pharmazeutische mittel und deren verwendung
AT03077455T ATE331719T1 (de) 1995-03-24 1996-03-22 Verwendung von kristallformen von 2- methylthienobenzodiazepinen

Country Status (49)

Country Link
US (1) US5736541A (de)
EP (3) EP0733635B1 (de)
JP (1) JPH11502535A (de)
KR (1) KR100399688B1 (de)
CN (1) CN1065536C (de)
AP (1) AP828A (de)
AR (2) AR002719A1 (de)
AT (4) ATE204280T1 (de)
AU (1) AU706471B2 (de)
BG (1) BG62619B1 (de)
BR (1) BR9607790A (de)
CA (1) CA2214005C (de)
CH (1) CH690579A5 (de)
CO (1) CO4650278A1 (de)
CZ (1) CZ292688B6 (de)
DE (4) DE19681286T1 (de)
DK (4) DK0733635T3 (de)
EA (1) EA000149B1 (de)
EE (1) EE03489B1 (de)
EG (1) EG23659A (de)
ES (3) ES2208220T3 (de)
FI (1) FI973750A0 (de)
GB (1) GB2313835B (de)
HK (1) HK1013988A1 (de)
HU (1) HU224989B1 (de)
IL (1) IL117610A (de)
IS (1) IS1896B (de)
LT (1) LT4349B (de)
LU (1) LU90096B1 (de)
LV (1) LV12018B (de)
MY (1) MY114701A (de)
NO (1) NO314663B1 (de)
NZ (1) NZ306110A (de)
OA (1) OA10510A (de)
PA (1) PA8353701A1 (de)
PE (1) PE44897A1 (de)
PL (1) PL183723B1 (de)
PT (3) PT1445259E (de)
RO (1) RO118872B1 (de)
SE (1) SE9703205L (de)
SI (4) SI1095941T1 (de)
SK (1) SK284143B6 (de)
SV (1) SV1996000031A (de)
TR (1) TR199701017T1 (de)
TW (2) TW442488B (de)
UA (1) UA44765C2 (de)
WO (1) WO1996030375A1 (de)
YU (1) YU49478B (de)
ZA (2) ZA962342B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
CA2232559A1 (en) * 1995-09-29 1997-04-03 Charles Merritt Beasley Jr. Method for treating a tic disorder
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
UA48219C2 (uk) * 1996-03-25 2002-08-15 Елі Ліллі Енд Компані Композиція для вгамування болю (варіанти) та спосіб вгамування болю
IL126063A (en) * 1996-03-25 2002-04-21 Lilly Co Eli Medicinal products containing ulanzapine for the treatment of migraine pain
BR9708246A (pt) * 1996-03-25 1999-07-27 Lilly Co Eli Metodo para tratamento de dor
WO1997035585A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Anesthetic method
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
EA001881B1 (ru) * 1996-09-23 2001-10-22 Эли Лилли Энд Компани Форма d дигидрата оланзапина
AU6955998A (en) * 1997-04-15 1998-11-11 Eli Lilly And Company Method for providing neuro-protective effects
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
EP1155696B1 (de) * 1997-04-15 2004-03-03 Eli Lilly And Company Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
UA66872C2 (uk) * 1998-09-30 2004-06-15 Елі Ліллі Енд Компані Сполука, яка є памоатом оланзапіну або його сольватом, та спосіб лікування психотичних розладів
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
WO2001047933A1 (en) * 1999-12-28 2001-07-05 Cipla Limited New polymorphic forms of olanzapine
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
SK2502003A3 (en) * 2000-08-31 2004-03-02 Reddys Lab Ltd Dr Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
WO2002019998A2 (en) * 2000-09-08 2002-03-14 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
WO2003037903A1 (en) * 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
AU2002367119A1 (en) * 2001-12-24 2003-07-15 Sun Pharmaceutical Industries Limited Crystalline form I of 2-methyl-4-(4-methyl-1-piperazinyl) 10H thieno [2,3-b][1,5]benzodiazepine
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
EP2266590A3 (de) 2002-02-22 2011-04-20 Shire LLC Wirkstoff-Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Wirkstoffen
AU2003213719A1 (en) * 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
WO2003101997A1 (en) 2002-05-31 2003-12-11 Geneva Pharmaceuticals, Inc. Process of preparation of olanzapine form i
AU2003243699B2 (en) * 2002-06-21 2009-01-15 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
SI21270A (sl) 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
AU2003300324A1 (en) 2002-12-24 2004-07-22 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
US20040242619A1 (en) * 2003-03-12 2004-12-02 Toth Zoltan G. Processes for preparation of polymorphic forms of desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
EP1684734A2 (de) * 2003-11-18 2006-08-02 3M Innovative Properties Company Olanzapin-haltige transdermale arzneimittelabgabezusammensetzungen
ES2308304T3 (es) * 2003-12-22 2008-12-01 Teva Pharmaceutical Industries Ltd. Procedimientos de preparacion de la olanzapina.
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
WO2006027800A1 (en) * 2004-09-06 2006-03-16 Shasun Chemicals And Drugs Limited A novel process for preparation of a pharmaceutically pure polymorphic form 1 of olanzapine
EA200701065A1 (ru) * 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
EP1838716B1 (de) 2005-01-05 2011-06-01 Eli Lilly And Company Olanzapinpamoat-dihydrat
CZ200563A3 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
WO2006102176A2 (en) * 2005-03-21 2006-09-28 Dr. Reddy's Laboratories Ltd. Process for preparing crystalline form i of olanzapine
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
EP1919923A1 (de) * 2005-08-17 2008-05-14 Synthon B.V. Verfahren zur herstellung von olanzapin form i
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (de) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Olanzapinreinigungsverfahren
SI3446565T1 (sl) 2010-08-23 2024-03-29 Alkermes Pharma Ireland Limited Metode zdravljenja povečanja teže, povzročene z antipsihotiki
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
EP2887952B1 (de) 2012-08-21 2019-05-15 Janssen Pharmaceutica NV Antikörper gegen olanzapinhaptene und verwendung davon
WO2014031645A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
PL2888590T3 (pl) 2012-08-21 2020-11-30 Janssen Pharmaceutica Nv Przeciwciała dla olanzapiny i ich zastosowanie
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
WO2023139531A1 (en) 2022-01-20 2023-07-27 Teva Pharmaceuticals International Gmbh Olanzapine, compositions thereof and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
AU668159B2 (en) * 1992-05-29 1996-04-26 Lilly Industries Limited Pharmaceutical compounds
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
EP1095941A1 (de) 2001-05-02
ES2208220T3 (es) 2004-06-16
GB2313835A (en) 1997-12-10
SI9620040A (sl) 1998-06-30
CN1065536C (zh) 2001-05-09
NZ306110A (en) 1998-09-24
ATE204280T1 (de) 2001-09-15
GB2313835B (en) 1998-09-16
US5736541A (en) 1998-04-07
YU17796A (sh) 1999-03-04
BR9607790A (pt) 1998-07-07
PE44897A1 (es) 1997-10-22
CA2214005A1 (en) 1996-10-03
SI1445259T1 (sl) 2006-10-31
LV12018B (en) 1998-09-20
AT406771B (de) 2000-08-25
CZ300097A3 (en) 1997-12-17
EP0733635B1 (de) 2001-08-16
DE69630324T2 (de) 2004-07-29
AP828A (en) 2000-04-28
WO1996030375A1 (en) 1996-10-03
EA000149B1 (ru) 1998-10-29
EE9700232A (et) 1998-04-15
SI9620040B (sl) 2002-02-28
FI973750A (fi) 1997-09-22
NO974365L (no) 1997-09-22
AU5427996A (en) 1996-10-16
EP1095941B1 (de) 2003-10-08
CN1179160A (zh) 1998-04-15
OA10510A (en) 2002-04-24
AU706471B2 (en) 1999-06-17
SE9703205D0 (sv) 1997-09-05
MX9707183A (es) 1997-11-29
LT4349B (lt) 1998-05-25
DK108997A (da) 1997-11-12
DE69614426T2 (de) 2002-05-23
PT733635E (pt) 2001-12-28
PT1095941E (pt) 2004-02-27
LT97148A (en) 1998-01-26
LU90096B1 (fr) 1997-07-22
PL183723B1 (pl) 2002-07-31
EA199700262A1 (ru) 1998-02-26
CO4650278A1 (es) 1998-09-03
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
NO314663B1 (no) 2003-04-28
HUP9802824A2 (hu) 1999-06-28
DK0733635T3 (da) 2001-10-08
ATE331719T1 (de) 2006-07-15
HU224989B1 (en) 2006-05-29
DE69630324D1 (de) 2003-11-13
AR002719A1 (es) 1998-04-29
DE69636313T2 (de) 2007-05-31
KR19980703188A (ko) 1998-10-15
SK121897A3 (en) 1998-03-04
KR100399688B1 (ko) 2004-02-18
BG101900A (en) 1999-03-31
IS4564A (is) 1997-09-22
FI973750A0 (fi) 1997-09-22
CZ292688B6 (cs) 2003-11-12
TW442488B (en) 2001-06-23
UA44765C2 (uk) 2002-03-15
EP0733635A1 (de) 1996-09-25
DK1095941T3 (da) 2004-02-16
TW513432B (en) 2002-12-11
SV1996000031A (es) 1998-03-27
LV12018A (lv) 1998-04-20
PL322501A1 (en) 1998-02-02
NO974365D0 (no) 1997-09-22
SI0733635T1 (en) 2002-06-30
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
YU49478B (sh) 2006-05-25
HK1013988A1 (en) 1999-09-17
IS1896B (is) 2003-10-20
ES2266719T3 (es) 2007-03-01
JPH11502535A (ja) 1999-03-02
MY114701A (en) 2002-12-31
DE69614426D1 (de) 2001-09-20
CA2214005C (en) 2001-07-03
ZA962342B (en) 1997-09-22
DE69636313D1 (de) 2006-08-10
SK284143B6 (sk) 2004-10-05
IL117610A0 (en) 1996-07-23
IL117610A (en) 2001-08-26
BG62619B1 (bg) 2000-03-31
CH690579A5 (de) 2000-10-31
HUP9802824A3 (en) 2000-01-28
DK1445259T3 (da) 2006-10-16
SE9703205L (sv) 1997-09-05
ATA902196A (de) 2000-01-15
ES2159346T3 (es) 2001-10-01
SI1095941T1 (en) 2003-12-31
EP1445259A1 (de) 2004-08-11
DE19681286T1 (de) 1998-04-02
EP1445259B1 (de) 2006-06-28
GB9719819D0 (en) 1997-11-19
EE03489B1 (et) 2001-08-15
TR199701017T1 (xx) 1998-01-21
EG23659A (en) 2007-03-26
ZA962344B (en) 1997-09-22
RO118872B1 (ro) 2003-12-30

Similar Documents

Publication Publication Date Title
ATE251627T1 (de) Verfahren und kristallformen von 2- methylthienobenzodiazepinen
DE69528265T2 (de) Quarzoszillator und verfahren zu seiner einstellung
DE69416907T2 (de) Verfahren zum Verbinden von Elementen und Verbindungsanordnung
DE69633983D1 (de) Inhibitoren von mikrosomalem triglycerid-transfer-protein und verfahren
ATE230606T1 (de) Verfahren zur vorbeugung und behandlung von allergien
ATE253116T1 (de) Verbesserte antikörper gegen ige und verfahren zur verbesserung von antikörpern
DE69322575T2 (de) Verfahren und Gerät zur Wiedergabe von abgeglichenen NURB Oberflächen
DE69618082D1 (de) Verfahren und Einrichtung zur Sprachsteuerung von Bildschirmanzeigen
DE69305426T2 (de) Verfahren zum Montieren von Bauteilen und Vorrichtung dafür
DE69419423D1 (de) Verfahren zur verkapselung und daraus hergestellte mikrokapseln
DE4394395T1 (de) Meßwertwandleranordnung und Verfahren
DE69533774D1 (de) Verfahren und system zur verteilten kontrolle von hardware
DE69612493T2 (de) Wickeldorn und verfahren zum kernlosen wickeln von klebeband
DE69504521T2 (de) Anzeigebeleuchtungsystem und verfahren
DE69518400T2 (de) Verfahren zum Verbinden von gewalzten Blechen und Vorrichtung dafür
DE69625292T2 (de) Interferometrischer Nahfeldapparat und Verfahren
DE69417022T2 (de) Elektrographischen element und verfahren
DE69431396D1 (de) Verfahren zur herstellung von n-tert-butyl-2-pyrazincarboxamid und n-tert-butyl-2-piperazincarboxamid
DE69629867D1 (de) Verfahren zum Zuführen und Auffangen von Lösungen
DE69630407D1 (de) Verwendung von reinigingsmitteln und verfahren zur flaschenreinigung
DE59509345D1 (de) Verfahren zur sprachsteuerung von anlagen und geräten
DE69616787T2 (de) Verfahren und anwendung von kontrastmitteln
DE59407138D1 (de) Verfahren zur nachbehandlung von betainen und amphoteren tensiden
KR970006689A (ko) 흙막이지지부재의 접합방법 및 접합블록
DE59602194D1 (de) Verfahren zum abbau von chinolonen und naphthyridonen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1095941

Country of ref document: EP